Shares of Stryker Corporation (SYK) jumped after the medical technology firm reported better-than-expected fourth-quarter results. The company's adjusted earnings per share reached $4.47, exceeding analyst estimates. Revenue also climbed, hitting $7.2 billion, fueled by double-digit growth in both sales and adjusted earnings, demonstrating strong performance in the market.

Stryker's strong performance in Q4 and throughout 2025 emphasizes the company's robust position within the medical device industry. Organic sales growth was a key driver, with the MedSurg and Neurotechnology segment leading the charge. The company's positive outlook for 2026, including projected organic sales growth between 8.0% and 9.5%, further boosted investor confidence.

For the full year 2025, Stryker saw an 11.2% increase in sales, reaching $25.1 billion. The company is projecting continued growth, citing strong demand for its products. Investors should watch Stryker's ability to maintain this momentum, especially in the face of ongoing economic uncertainties. Further developments in the medical technology sector will be key.